Fig. 6From: Glaucocalyxin A delays the progression of OA by inhibiting NF-κB and MAPK signaling pathwaysThis model demonstrates that GLA is a promising medication for the treatment of OA by blocking the NF-κB, ERK, and JNK pathways in chondrocytes to reduce inflammatory factor production and maintain extracellular homeostasisBack to article page